- Home
- HTOO vs KPRX Comparison
HTOO vs KPRX Comparison
Compare HTOO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- KPRX
- Stock Information
- Founded
- HTOO 2020
- KPRX 1998
- Country
- HTOO Ireland
- KPRX United States
- Employees
- HTOO N/A
- KPRX N/A
- Industry
- HTOO Natural Gas Distribution
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HTOO Utilities
- KPRX Health Care
- Exchange
- HTOO Nasdaq
- KPRX Nasdaq
- Market Cap
- HTOO 12.3M
- KPRX 11.0M
- IPO Year
- HTOO N/A
- KPRX N/A
- Fundamental
- Price
- HTOO $0.38
- KPRX $3.21
- Analyst Decision
- HTOO Strong Buy
- KPRX Strong Buy
- Analyst Count
- HTOO 1
- KPRX 1
- Target Price
- HTOO $3.50
- KPRX $10.00
- AVG Volume (30 Days)
- HTOO 501.4K
- KPRX 45.3K
- Earning Date
- HTOO 12-02-2024
- KPRX 11-19-2024
- Dividend Yield
- HTOO N/A
- KPRX N/A
- EPS Growth
- HTOO N/A
- KPRX N/A
- EPS
- HTOO N/A
- KPRX 1.53
- Revenue
- HTOO $4,580,524.00
- KPRX $16,020,000.00
- Revenue This Year
- HTOO $440.97
- KPRX N/A
- Revenue Next Year
- HTOO $214.20
- KPRX N/A
- P/E Ratio
- HTOO N/A
- KPRX $2.29
- Revenue Growth
- HTOO N/A
- KPRX N/A
- 52 Week Low
- HTOO $0.32
- KPRX $3.00
- 52 Week High
- HTOO $4.65
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- HTOO 39.02
- KPRX 43.73
- Support Level
- HTOO $0.32
- KPRX $3.47
- Resistance Level
- HTOO $0.81
- KPRX $3.75
- Average True Range (ATR)
- HTOO 0.10
- KPRX 0.22
- MACD
- HTOO -0.02
- KPRX -0.03
- Stochastic Oscillator
- HTOO 18.37
- KPRX 0.00
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.